Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3475766 - IV
LY3475766 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3475766 - IV | EXPERIMENTAL | LY3475766 administered intravenously (IV) to participants with dyslipidemia |
| Placebo - IV | PLACEBO_COMPARATOR | Placebo administered IV to participants with dyslipidemia |
| LY3475766 - SC | EXPERIMENTAL | LY3475766 administered subcutaneously (SC) to participants with dyslipidemia |
| Placebo - SC | PLACEBO_COMPARATOR | Placebo administered SC to participants with dyslipidemia |
| Name | Type | Description |
|---|---|---|
| LY3475766 - IV | DRUG | Administered IV |
| LY3475766 - SC | DRUG | Administered SC |
| Placebo - IV | DRUG | Administered IV |
| Placebo - SC | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy males or females, apart from dyslipidemia * Male participants must agree to adhere to contraception restrictions * Female participants must be of nonchildbearing potential and include those who are infertile due to surgical sterilization or those who are po...
LY3475766 is an investigational small molecule being developed by Eli Lilly and Company for dyslipidemias, a group of conditions involving abnormal levels of lipids such as cholesterol and triglycerides in the blood. It is in Phase 1 clinical development.
LY3475766 is being studied for dyslipidemias, which are disorders of lipid metabolism. It has been evaluated in a Phase 1 trial in healthy participants, and no approved use has been established. It remains an investigational therapy.
LY3475766 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating the compound.
LY3475766 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no later-stage trials are currently active. The compound has not been approved for any indication and remains investigational.
LY3475766 has been studied in one Phase 1 trial, NCT04052594, titled A Study of LY3475766 in Healthy Participants. The trial enrolled 48 healthy volunteers in the United States, was randomized, double-blind, and placebo-controlled, and has been completed.
Yes, LY3475766 - IV is an alternative name for LY3475766. Both refer to the same investigational small molecule developed by Eli Lilly and Company for dyslipidemias.